NKGEN BIOTECH, INC.

Highlights NKGen Biotech, Inc.

Equities

NKGN

US65488A1016

End-of-day quote Nasdaq Other stock markets 03:30:00 05/06/2024 am IST			5-day change	1st Jan Change
1.45 ^USD	+0.69%		-13.17%	-47.27%

03/06	NKGen Biotech, Inc. To Present Updated Phase 1 Data on SNK02 Allogeneic NK Cell Therapy in Solid Tumors at the 6th Annual Allogeneic Cell Therapies Summit 2024	CI
23/05	NKGen Biotech Publishes Phase 1 Interim Analysis Results of SNK02 Allogeneic NK Cell Therapy in Advanced Solid Tumors at the 2024 American Society of Clinical Oncology Annual Meeting	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

NKGen Biotech, Inc. To Present Updated Phase 1 Data on SNK02 Allogeneic NK Cell Therapy in Solid Tumors at the 6th Annual Allogeneic Cell Therapies Summit 2024	03/06	CI
NKGen Biotech Publishes Phase 1 Interim Analysis Results of SNK02 Allogeneic NK Cell Therapy in Advanced Solid Tumors at the 2024 American Society of Clinical Oncology Annual Meeting	24/05	CI
NKGen Biotech, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	21/05	CI
Top Midday Gainers	20/05	MT
Sector Update: Health Care Stocks Ease Monday Afternoon	20/05	MT
NKGen Biotech Cell Therapy Gets Clearance to Start Phase 2 Clinical Trial in Alzheimer's Disease; Shares Rise	20/05	MT
NKGen Biotech, Inc.?s SNK01 NK Cell Therapy Cleares to Start Phase 2 Clinical Trial in Alzheimer?s Disease	20/05	CI
Nkgen Biotech Announces FDA Clearance of Investigational New Drug Application for SNK01 NK Cell Therapy in Parkinson's Disease	29/04	CI
NKGen Biotech, Inc. Announces Upcoming Presentation on SNK01 NK Cell Therapy in Neurodegenerative Disease at the 12th Annual Alzheimer's & Parkinson's Drug Development Summit	19/04	CI
NKGen Biotech, Inc. Presents Additional Phase 1 Clinical Trial Data in Alzheimer?s Disease At the Tau2024 Global Conference	26/03	CI
Exchange-Traded Funds Lower, Equity Futures Flat Pre-Bell Friday	29/12	MT
NKGen Biotech, Inc. Announces Dosing of First Patient in its Phase 1/2a Trial with Autologous NK Cell Product, SNK01, for the Treatment of Moderate Alzheimer's Disease	29/12	CI
NKGen Biotech Gets Canadian Regulator's Clearance to Study NK Cell Therapy for Alzheimer's	27/12	MT
NKGen Biotech Inc. Announces Clearance of Clinical Trial Application by Health Canada for SNK01 NK Cell Therapy to Treat Alzheimer's Disease	27/12	CI
Nkgen Biotech Presented Phase I Clinical Trial Data At the 16Th Annual Clinical Trials on Alzheimer's Disease Conference	26/23/26	CI
NKGen Biotech Gets FDA Clearance to Start Alzheimer's Disease Trial; Shares Jump	24/23/24	MT
NKGen Biotech, Inc. Announces FDA Clearance of Investigational New Drug Application for SNK01 NK Cell Therapy to Treat Alzheimer's Disease	24/23/24	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

+201.5% on SUPER MICRO COMPUTER since our purchase on February 17, 2023

Replicate our performance

fermer